Margo Heath-Chiozzi - Aug 11, 2021 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
SVP of Regulatory Affairs
Signature
/s/ Sam Martin, attorney-in-fact for Margo Heath-Chiozzi
Stock symbol
CLDX
Transactions as of
Aug 11, 2021
Transactions value $
$90,165
Form type
4
Date filed
8/13/2021, 06:59 AM
Previous filing
Jun 21, 2021
Next filing
Nov 3, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $90.2K +10K +801.92% $9.02 11.2K Aug 11, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option Options Exercise $0 -10K -54.55% $0.00 8.33K Aug 11, 2021 Common Stock 10K $9.02 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 247 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F2 This option was previously reported as covering 275,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.
F3 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters